Daily Newsletter

29 September 2023

Daily Newsletter

29 September 2023

Nanostics introduces blood test for prostate cancer in Alberta, Canada

ClarityDX Prostate helps reduce prostate biopsies by up to 35%, thereby significantly reducing costs.

RanjithKumar Dharma September 29 2023

Diagnostic test provider Nanostics has initiated a new blood test for prostate cancer screening in Alberta, Canada.

The ClarityDX Prostate test is available at the company’s clinical lab in Edmonton.

Developed to offer critical support to men aged between 40 and 45, the test will enable physicians to make informed decisions with greater accuracy.

It will help confirm the use of a biopsy after a high prostate-specific antigen test result.

Nanostics CEO Dr John Lewis said: “This test will reduce the number of unnecessary prostate biopsies, which are invasive, uncomfortable and carry some risk.”

Research demonstrated that the addition of ClarityDX Prostate to the patient care pathway could lower unnecessary prostate biopsies by up to 35%, thereby significantly reducing costs.

The Alberta Prostate Cancer Research Initiative, the University of Alberta and global research institutions have supported the company in developing and validating this test.

ClarityDX is the company’s core technology that leverages machine learning algorithms to create a disease risk score. It can be used for a wide range of cancers and other diseases.

Alberta Cancer Foundation CEO Wendy Beauchesne said: “We are dedicated to creating more moments for Albertans facing cancer and it's a mission we share with Dr Lewis and the Nanostics team.

“Through the launch of ClarityDX Prostate, we are enhancing detection and treatment options. It's incredible to see what can happen when Albertans come together to support big ideas.”

Generative AI set to transform the medical devices industry

Generative AI can improve personalized healthcare by collecting data from patients via wearable devices, which can provide continuous, real-time data that can complement traditional data sources such as imaging, patient records, and more. It can also enhance existing imaging techniques by generating high-quality images of organs using data from low-resolution images (such as ultrasounds). However, the collection and use of patient healthcare data through AI medical products could conflict with regulations around the globe.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close